Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a small phase I study with dose escalation and dose expansion cohorts. The former
cohort will need up to 12 subjects with advanced solid tumor to define feasibility and
recommended phase 2 dose (RP2D); the latter up to 10 subjects to further define safety. Study
subjects will be adults with advanced solid tumor (dose escalation) and advanced non-small
cell lung cancer (NSCLC) who progressed on at least one first-line systemic therapy (dose
expansion).